JNM publishes consensus statement on patient selection and appropriate use of Lu-177 PSMA-617 radionuclide therapy
Reston, VA—The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177Lu-PSMA radionuclide therapy. The statement, published in the July issue of The Journal of Nuclear Medicine, also reviews current clinical struggles physicians face during treatment with 177Lu-PSMA-617 radionuclide therapy.
Recently, the U.S. Food and Drug Administration approved 177Lu-PSMA-617 for the treatment of men with mCRPC after progressing on taxane-based chemotherapy ...







